Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection - PubMed (original) (raw)
Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection
Helle Krogh Johansen et al. Pediatr Pulmonol. 2004 May.
Abstract
We studied the effects of increasingly intensive treatment regimens on anti-pseudomonal antibody response and survival in five successive cohorts of a total of 157 Danish cystic fibrosis patients after they had acquired chronic P. aeruginosa lung infection. The time periods were 1971-1975 (N = 21), 1976-1980 (N = 64), 1981-1986 (N = 27), 1987-1993 (N = 26), and 1994-2000 (N = 19). During this 30-year period, we introduced elective 2-week courses of chemotherapy every third month in all chronically infected patients, early aggressive treatment with inhalation of colistin and oral ciprofloxacin for 3 months whenever P. aeruginosa was cultured in sputum from noncolonized patients, and inhalation of recombinant human dornase alfa. There was a significant correlation between the calendar year when chronic P. aeruginosa infection was acquired and the subsequent increase in the level of precipitins (P < 0.00001). The median number of precipitins increased by 5 per year in the oldest calendar year cohort, and 1 per year in the youngest. The median age of onset of chronic P. aeruginosa increased from 9.3 years from 1981-1986 to 13.8 years from 1987-2000. Survival after acquisition of chronic P. aeruginosa lung infection improved with time (P = 0.008). Our study shows that CF patients who are treated intensively have lower antibody responses and longer survival after acquisition of chronic P. aeruginosa lung infection.
Copyright 2004 Wiely-Liss, Inc.
Similar articles
- Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR, Pressler T, Høiby N. Hansen CR, et al. J Cyst Fibros. 2008 Nov;7(6):523-30. doi: 10.1016/j.jcf.2008.06.009. Epub 2008 Aug 9. J Cyst Fibros. 2008. PMID: 18693078 - Eradication of early Pseudomonas aeruginosa infection.
Høiby N, Frederiksen B, Pressler T. Høiby N, et al. J Cyst Fibros. 2005 Aug;4 Suppl 2:49-54. doi: 10.1016/j.jcf.2005.05.018. J Cyst Fibros. 2005. PMID: 16023416 Review. - Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient. Cantón R, et al. Clin Microbiol Infect. 2005 Sep;11(9):690-703. doi: 10.1111/j.1469-0691.2005.01217.x. Clin Microbiol Infect. 2005. PMID: 16104983 Review.
Cited by
- Lung immunoglobulin A immunity dysregulation in cystic fibrosis.
Collin AM, Lecocq M, Noel S, Detry B, Carlier FM, Aboubakar Nana F, Bouzin C, Leal T, Vermeersch M, De Rose V, Regard L, Martin C, Burgel PR, Hoton D, Verleden S, Froidure A, Pilette C, Gohy S. Collin AM, et al. EBioMedicine. 2020 Oct;60:102974. doi: 10.1016/j.ebiom.2020.102974. Epub 2020 Sep 11. EBioMedicine. 2020. PMID: 32927272 Free PMC article. - In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections.
Yang L, Haagensen JA, Jelsbak L, Johansen HK, Sternberg C, Høiby N, Molin S. Yang L, et al. J Bacteriol. 2008 Apr;190(8):2767-76. doi: 10.1128/JB.01581-07. Epub 2007 Dec 21. J Bacteriol. 2008. PMID: 18156255 Free PMC article. - Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies.
Friman VP, Ghoul M, Molin S, Johansen HK, Buckling A. Friman VP, et al. PLoS One. 2013 Sep 19;8(9):e75380. doi: 10.1371/journal.pone.0075380. eCollection 2013. PLoS One. 2013. PMID: 24069407 Free PMC article. - Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.
Bartell JA, Sommer LM, Marvig RL, Skov M, Pressler T, Molin S, Johansen HK. Bartell JA, et al. Eur Respir J. 2021 Apr 8;57(4):2000512. doi: 10.1183/13993003.00512-2020. Print 2021 Apr. Eur Respir J. 2021. PMID: 33093121 Free PMC article. - Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis.
Corech R, Rao A, Laxova A, Moss J, Rock MJ, Li Z, Kosorok MR, Splaingard ML, Farrell PM, Barbieri JT. Corech R, et al. J Clin Microbiol. 2005 Aug;43(8):3956-62. doi: 10.1128/JCM.43.8.3956-3962.2005. J Clin Microbiol. 2005. PMID: 16081936 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical